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Abstract
Transforming Growth Factor – beta (TGFb) superfamily ligands, including Activins, Growth and Differentiation Factors
(GDFs), and Bone Morphogenetic Proteins (BMPs), are excellent targets for protein-based therapeutics because of their
pervasiveness in numerous developmental and cellular processes. We developed a strategy termed RASCH (Random
Assembly of Segmental Chimera and Heteromer), to engineer chemically-refoldable TGFb superfamily ligands with unique
signaling properties. One of these engineered ligands, AB208, created from Activin-bA and BMP-2 sequences, exhibits the
refolding characteristics of BMP-2 while possessing Activin-like signaling attributes. Further, we find several additional
ligands, AB204, AB211, and AB215, which initiate the intracellular Smad1-mediated signaling pathways more strongly than
BMP-2 but show no sensitivity to the natural BMP antagonist Noggin unlike natural BMP-2. In another design, incorporation
of a short N-terminal segment from BMP-2 was sufficient to enable chemical refolding of BMP-9, without which was never
produced nor refolded. Our studies show that the RASCH strategy enables us to expand the functional repertoire of TGFb
superfamily ligands through development of novel chimeric TGFb ligands with diverse biological and clinical values.
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Introduction
The Transforming Growth Factor-beta (TGFb) superfamily
ligands encompass several subfamilies consisting of TGFb, Bone
Morphogenetic Proteins (BMPs), Activin and Inhibin, Growth and
Differentiation Factors (GDFs), Nodal, and Mu ¨llerian Inhibiting
Substance (MIS). Since TGFb1, the founding member of the
superfamily, was first discovered by Roberts and her colleagues
[1], 33 such TGFb superfamily ligands have been identified in the
human genome. These superfamily ligands collectively function in
a diverse range of cell types and play important roles in
fundamental cellular events including dorsal/ventral patterning
and left/right axis determination as well as bone formation and
tissue and organ development [2]. By the same token, many TGFb
superfamily ligands are being actively explored for their potential
ability to guide the in vivo and ex vivo differentiation pathways or for
the ex vivo maintenance of stem cells at various stages [3,4, and
more recent references herein]. Due to their overlapping
pervasiveness in their intercellular signaling capabilities, medical
intervention of these signaling pathways by TGFb superfamily
ligand holds great promise to develop new treatments of a wide
range of different developmental diseases from skeletal and muscle
abnormalities to a multitude of neoplastic disorders [5–7].
One of the hallmark features of TGFb superfamily ligands is
that they are synthesized as inactive precursor molecules
composed of an N-terminal pro-domain and a C-terminal mature
domain, which must be cleaved from the pro-domain to become
active (e.g. BMP-4) [8]. TGFb superfamily members are classified
based on the conserved structural architecture found in their
mature domains. In general, each mature ligand monomer
contains 7 cysteines, 6 of which are arranged in the ‘cystine knot’
motif [9]. The last 7th cysteine forms an inter-disulfide bond
between two chains, generating a covalently linked dimer.
Stretching outward structurally from the centrally located ‘cystine
knot’ of the dimer are mainly 4 beta strands forming 2 curved
fingers. This gives the dimer the overall appearance of a butterfly.
The functional subunit for the TGFb superfamily can exist both as
homo- and hetero-dimers in vivo [10–13]. Some family members,
such as GDF9 and BMP15, lack the cysteine required to form the
inter-disulfide bond, yet they are still functional and able to form
stable dimers [14].
To initiate the signaling process, TGFb superfamily dimers
must interact with two sets of receptors, termed type I and type II.
Both receptors are composed of N-terminal ligand-binding
extracelluar domain and C-terminal intracellular serine/threonine
kinases. TGFb superfamily ligands display preferences in their
affinity between the two different receptor types. TGFb, Activin,
Nodal, and BMP-7 exhibit high affinity for type II receptors,
whereas BMP-2 and GDF-5 possess higher affinity for type I
receptors [15]. Following the binding of two high affinity
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binding of all four receptors to the ligand, forming a 6-member
ternary complex, the downstream signaling response can be
initiated [16]. The constitutively active type II receptors
phosphorylate the type I receptors which, in turn, bind and
phosphorylate intracellular signaling molecules called Smads. The
activated Smad molecules are then able to translocate to the
nucleus and interact directly with transcriptional regulators
[17,18]. Therefore, multiple mechanisms can be employed to
regulate TGFb signaling at various stages of the signaling cascade.
Extracellular antagonists (e.g. Noggin and Follistatin) by seques-
tering the ligands from binding their cell surface receptors, cell
surface pseudo-receptors lacking the intracellular kinase domain
(e.g. BAMBI) by interfering with the phosphorylation step, and
intracellular molecules, such as inhibitory Smads by blocking the
entry into the nucleus, can play a critical biological role in
controlling the signal to reach the nucleus from outside the cell
[18,19].
One of the most intriguing features of the TGFb superfamily is
the high degree of promiscuity displayed by TGFb superfamily
ligands and their receptors. For 33 TGFb ligands, there are only
12 receptors (7 type I and 5 type II), with which one of each type
needs to bind to a single ligand to initiate the signaling cascade.
TGFb superfamily ligands indeed interact with a multitude of
different receptors with varying affinity and specificity. For
instance, BMP-2 is known to preferentially bind BMPRII, but is
also capable of interacting with ActRII and ActRIIb [20]. The
structural details of how ligand:receptor affinity and specificity are
regulated and their implications on overall signaling fate are just
beginning to be understood. In GDF-5, a single amino acid has
been identified for selecting its type I receptor preference [21],
while in BMP-3 a single point mutation was discovered which not
only alters type II receptor affinity but also endows the ligand with
signaling properties [22]. These studies suggest a direct correlation
between ligand function and receptor binding and outline a
method to altering signaling outcomes through modification of
receptor binding patterns.
Although all these TGF-beta superfamily ligands and their
sequence variants are of potential therapeutic use, the inability to
produce readily significant quantities of pure, active TGFb
superfamily ligands has been a significant barrier to fully explore
their clinical potential. Only a limited number of BMP/GDF
family ligands have been successfully produced bacterially and
refolded to high yields, which include BMP-2, BMP-3, BMP-6,
and GDF-5 [21–24]. E. coli production and the chemical refolding
of other ligands, such as Activin bA and BMP-7, have been
reported [25], but repeating these results has proven to be difficult.
Alternatively, eukaryotic expression systems can be successfully
used to obtain certain TGFb superfamily ligands. Activin-bA has
been expressed using stably transfected cell lines, such as CHO
cells [26], or transiently transfected cell lines, such as HEK cells
[27]. Although these expression systems produce active and
posttranslationally-modified TGFb ligands, they can require long
periods of time to establish a production cell line, and be
inadequate for screening a large number of sequence variants. The
chemical refolding process starting from inclusion body isolated
from E. coli culture as we used for this study offers a time-effective
alternative to produce and screen TGFb superfamily ligands and
their variants.
In the current study, we developed a segmental gene cloning
strategy termed ‘Random Assembly of Segmental Chimera and
Heteromers (RASCH)’, by which one can create TGFb
superfamily ligands and their chimeric variants with unique
characteristics. By applying the RASCH strategy to Activin-bA
and BMP-2 sequences, we demonstrate the ability to generate an
Activin/BMP-2 (AB2) chimera library, from which we found
AB208 with the refolding efficiency of BMP-2 and the signaling
properties of Activin-bA. This strategy also produced a significant
number of AB2 chimera ligands possessing unique receptor
binding and cell signaling properties. Three of these AB2 chimeric
ligands, AB204, AB211, and AB215, displayed higher signaling
activity compared to BMP-2 and the activity could not be
attenuated by the extra- Noggin. In another example, inclusion of
a small N-terminal section of BMP-2 was sufficient to develop a
functional, efficient refolding of BB29, which resembles the activity
of BMP-9. These results provide a groundwork to diversify the
biological functions of TGFb superfamily ligands using the
RASCH strategy to expand their clinical potential as novel
therapeutic agents.
Results
Design Strategy for Chimeric TGFb family Ligands
The overall RASCH strategy to create our novel TGFb
superfamily ligands is based on a modified directed evolution
approach, by which we systematically swap five intact, defined
protein segments of two or more TGFb superfamily ligands
instead of random mutagenesis or gene shuffling [28]. This initial
approach involved Activin and BMP-2 as two target genes, with
which we created, refolded and screened 32 (2
5) chimeric variants
that we refer to as Activin/BMP-2 (AB2) library chimeras. For this
experiment, Activin-bA is termed the target ligand because we
have not been able to refold despite a report of successful refolding
of Activin-bA [25]. BMP-2 is termed the template ligand because
we can refold it with excellent efficiency. Typically, .10% BMP-2
dimer product was yielded starting from denatured inclusion
bodies, and these dimers have been used in both in vitro and in vivo
experiments and for crystal structure determination [23,29].
Sequence boundaries of the five segments of Activin-bA and
BMP-2 to create the AB2 chimeras were defined on the basis of
their structural elements and the sequence similarity between
them. Initially, the crystal structures of Activin-bA [29] and BMP-
2 [23] were compared and 6 distinct structural segments were
identified to minimize disruption of their secondary structural
elements thus to conserve local structural elements as a result of
swapping (Figure 1A–C). The exact segment boundaries were
further refined following a protein sequence alignment of these
ligands (Figure 1A–C), with additional adjustment of segmental
boundaries to allow amino acids conserved for segment swapping
universally (universal joints) among the entire TGFb superfamily
ligands as seamlessly as possible. More specifically, the pre-helix
loop and the majority of the a-helix were combined into Segment
3, while the remainder of the a-helix and the beginning of beta
strand 3 were placed into Segment 4 (Figure 1A–C, yellow and
green). A few additional point mutations were necessary to create
universal joints between certain segments. At the end of Segment
3, TLVN of BMP-2, which corresponds to TVIN of the Activin-
bA sequence, was taken as the consensus sequence (Figure 1A, red
box). At the end of Segment 5, LYLD of BMP-2 is equivalent to
LYYD of Activin-bA (Figure 1A, blue box), for which LYYD was
taken as the consensus sequence. Finally, the N-terminus of
Activin-bA contains 2 additional cysteines, forming form a 4
th
intra-disulfide bond, compared to BMP-2 (Figure 1A, yellow
boxes). To avoid the potential complication in the refolding
process by these extra disulfide bond, Segment 1 of Activin-bA was
removed from the final pool of segments, thus it consists of 11
Segments (Segments 1 through 6 of BMP-2 and Segments 2
through 6 of Activin-bA).
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Each of the 32 AB2 chimera vectors (AB201 through AB232)
was assembled individually by PCR from the Activin-bA and
BMP-2 segments, and they were expressed using a standard E. coli
expression system. Surprisingly, all AB2 library chimeras were
found in the inclusion body fractions, isolated to high purity and
seen as bands around 13 kDa by SDS-PAGE analysis. To
standardize the refolding protocol, all AB2 chimeras were refolded
in 100 mL volumes at a concentration of 50 mg/L. The
concentration was chosen based on successful refolding conditions
known for various TGF-beta superfamily ligands including BMP-
2, BMP-3, and GDF-5 [23]. The refolding volume was sufficient to
ensure that a dimerization yield at the level of 2% or greater
results in sufficient quantity to obtain enough protein for
biophysical and cell signaling assays, yet the volume still be small
enough to be manageable to process the large number of samples
simultaneously.
The first evaluation of proper refolding is the formation of
dimeric ligand, and all 32 AB2 chimera samples showed the
presence of varying degrees of dimer product as determined by
non-reduced SDS-PAGE analysis. At this stage, the refolding
efficiency was estimated based on the dimerization efficiency,
based on which each AB2 chimera was placed into a category
ranging from poor (1% or less, 2), medium (1–5%), high (5–10%),
and highest (.10%, +++) (Table S1). Natural BMP-2 ligand was
calibrated as 10% efficiency in comparison. They were classified as
a ‘good’ refolder if the refolding efficiency was equal to or greater
than 5%. This efficiency of 5% yielding 2.5 mg/L of dimeric
protein from a standard 1 L refolding at 50 mg/L would be
considered suitable for experiments where large quantities are
required. Based on this evaluation, we found that 19 out 32
(,60%) of the AB2 chimeras met the standard of a ‘good’ refolder
(Table S1, ++ or +++).
Activin-bA Characteristics of AB208 Chimera
Signaling properties of all AB2 chimeras, regardless of refolding
efficiency, were subjected to cell-based activity assays. Activin-bA
is known to signal through and activate the Smad2/3 pathway.
Using a whole cell luciferase reporter assay sensitive to Smad2
activation, the AB2 chimeras were tested for signaling through
Smad2/3 pathway. Out of all AB2 32 chimeras, AB208 is the only
one that activated the luciferase reporter in a dose-dependent
manner similar to Activin-bA (Figure 2A). AB208 is also referred
to by the segmental codename 1b2a3a4a5a6a, which shows that it
contains all Activin-bA segments except Segment 1 from BMP-2.
Each number in the codename denotes the segment number 1
through 6, and A is for Activin-bA, B is for BMP-2 sequences, and
AB2 is a chimera between Activin and BMP-2. We measured that
the EC50 of AB208 is 76.6 pM. This value is only approximately 5
fold weaker than wild-type Activin-bA (15.8 pM, Figure 2D).
Despite its slightly decreased signaling activity, AB208 achieved
the same maximal response as Activin-bA (Figure 2A).
To confirm the SMAD2/3 signaling pathway due to Smad2
activation, we tested for the presence of phospho-Smad2. As with
Activin-bA, we find that AB208 promotes an increase in phospho-
Smad2 levels and not phospho-Smad1 levels (Figure S1). Further,
in a Smad1-dependent luciferase assay, AB208 did not exhibit a
signaling response, even up to levels of 1 mg/ml. Combined, these
Figure 1. Segmental Design Strategy. Activin/BMP-2 (AB2) chimeras were designed based on structural and sequence considerations. A)
Sequence alignment of BMP-2 and Activin-bA with the segments colored and labeled. Yellow boxes indicate Cys residues in Segment 1 of Activin-bA
and the Green box highlights the sequence changed to make AB210, while Red and Blue boxes highlight differences in sequence at the boundary
regions. How the segments divide the ligands are illustrated in the monomer structure of BMP-2 (B) and Activin-bA (C), with the segment matching
the color of sequence box (A). Sulfur atoms of disulfide bonds are represented as yellow spheres.
doi:10.1371/journal.pone.0026402.g001
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pathway similarly to Activin-bA. We conclude that the designer
ligand AB208 exhibits the same signaling functionality like
Activin-bA, and it can be produced bacterially from inclusion
body with the dimerization yield greater than 10% exceeding that
of BMP-2 (Table S1).
Additional Activin-like Chimeras, AB209 and AB210
Based on the results of AB208, two additional AB chimeras were
generated to introduce Activin-bA amino acids back to AB208.
AB209 was created by re-introducing the Val-Ile of Activin-bA
found at the boundary of segments 3 and 4 into the AB208, where
these amino acids of Activin-bA were changed to the correspond-
ing BMP-2 residues Leu-Val due to experimental design
constraints (Figure 1A, red boxes). Another chimera, AB210,
was created by replacing the C-terminal half of the 1b segment by
the equivalent sequence segment of Activin-bA (Figure 1A, green
box). This replacement leaves only the 13 N-terminal residues
preceding the first structurally conserved Cys-14 (Figure 1A,
residues 1–13 BMP-2 numbering), as well as Leu-66, and Val-67
(Figure 1A, BMP-2 numbering) in AB210 as amino acids from
BMP-2. AB209 and AB210 were expressed but they were not
refolded as efficiently as AB208 (Table S1).
Following refolding and purification, AB209 and AB210 were
subjected to the same Smad2 luciferase assay as previously
performed with AB208. Functionally, AB209 activated the Smad2
reporter in a dose-dependent manner and displayed activity slightly
weaker (less than 2-fold) than AB208 with an EC50 of 149 pM
(Figure 2B, 2D). AB210 also activated the Smad2 reporter activity
with an EC50 of 325 pM (Figure 2C, 2D), thus it is ,4-fold weaker
than AB208 or ,20-fold weaker than Activin-bA (Figure 2D). As
with AB208, both AB209 and AB210 showed specific activation of
phospho-Smad2 levels (Figure S1). Since AB208’s signaling was the
closest to Activin-bA in the Smad2-dependent signaling assays, we
focused on AB208 for further characterization.
Receptor Binding Properties of AB208
To address if AB208 signals through and interacts with known
Activin-bA receptors similar to Activin-bA, we compared the
receptor binding affinities between Activin-bA and AB208 by
surface plasmon resonance (Biacore). Activin-bA is known to bind
its type II receptors, ActRII and ActRIIb, with high affinity. In our
Biacore assay, Activin-bA showed a binding affinity of
KD=0.203 nM against ActRII-ECD immobilized to the chip
surface (Table 1). In similar experiments, Activin-bA has been
shown to bind ActRII and ActRIIb with sub-nanomolar affinities
[29,30]. When AB208 was passed over the same surface, a binding
affinity of KD=0.344 nM was calculated (Table 1). This result
indicates that AB208 exhibits nearly identical type II receptor
binding properties as Activin-bA.
Cripto-mediated Signaling Property of AB208
Along with the type I and type II receptors, additional TGFb
modifiers or co-receptors play roles in directing TGFb ligand
Figure 2. Smad2 Activity Assays. The activity of Activin-bA was compared to (A) AB208, (B) AB209, and (C) AB210 using Smad2 dependent
luciferase reporter in HEK293 cells and is presented as Fold Induction. (D) The EC50 and relative potency for each ligand are shown. The experiments
were performed in triplicate and the error bars are included.
doi:10.1371/journal.pone.0026402.g002
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diverse range of responses. For instance, the presence of Cripto is
required for positive Nodal signaling [31], while it antagonizes
Activin-bA [32] signaling. To test if AB208 interacts with Cripto
in the same manner as Activin-bA, we measured Smad2 reporter
activity in the presence and absence of Cripto. When Cripto was
added, Activin-bA signaling was decreased by ,57% compared to
the level achieved by Activin-bA without Cripto (Figure 3A). This
reduction in Activin-bA signaling upon the addition of Cripto is
consistent with previously reported results [33]. We observe that
AB208 signaling was lowered by ,66% with the addition of
Cripto in the same experimental conditions (Figure 3B). Together,
the data suggests AB208 possesses the same receptor binding
profiles as Activin-bA.
1B Segment Improves Refolding of BMP-9
AB208 distinguishes itself from Activin-bA by the presence of
the ‘1b’ Segment of BMP-2 and two amino acids (Leu66-Val67).
The successful refolding of the AB208 suggested that the ‘1b’
segment contains certain sequence characteristics that may be
more universally applicable as a tool to improve the refolding of
other currently non-refoldable TGFb ligands. The ‘1b’ segment
comprises the N-terminal residues of BMP-2 forming the first beta
strand of finger 1 (Figure 1A, 1B). The analysis of the crystal
structure of the ternary complex of BMP-2/BMPRIa-ECD/
ActRII-ECD [23] indicates that the majority of the residues found
in the ‘1b’ segment do not form contacts with either the type I or
type II receptors (data not shown). Therefore, transplanting the 1b
segment is unlikely to affect receptor-binding properties of the
engineered ligands. We have chosen BMP-9 to test the idea, which
exhibits diverse biological functions from involvement in cartilage
and bone development to playing a role in glucose regulation
[34,35]. While BMP-9 can be successfully expressed using a CHO
cell line [36], BMP-9 has not been refolded in vitro from inclusion
bodies. A new designer ligand termed 1b_BMP-9 has been
created, for which the ‘1b’ Segment of BMP-2 replaced the
equivalent segment of BMP-9. 1b_BMP-9 was expressed, refolded,
and purified by same methods used for the AB chimeras.
With respect to the refolding characteristics of 1b_BMP-9,
1b_BMP-9 remains in solution with no visible precipitation,
whereas BMP-9 largely precipitates out of solution after 72 hrs in
the same refolding condition. With respect to the elution profile
from heparin Sulfate purification step, 1b_BMP-9 shows a shift in
peaks towards later elution times (Figure 4A, 4B), whereas BMP-
9’s elution profile displays large peaks early in the run. The total
amount of protein available from the refolding step is significantly
higher for 1b_BMP-9 than BMP-9. More importantly, when the
1b_BMP-9 elution fractions were run on a SDS-PAGE gel under
non-reducing conditions, a band at ,26 kD, corresponding to the
expected dimer size of BMP-9, is mostly present only in fraction 5
(Figure 4C). The area of this peak for 1b_BMP-9 is at least 10-fold
larger than the same peak of BMP-9 (Figure 4A, 4B). The overall
yield for the 1b_BMP-9 refolding was calculated to be ,7%,
Table 1. Receptor affinity of BMP-2, Activin A, and AB2 chimeras.
Ligand (Chimera segments) BMPRIa-ECD ActRII-ECD
koff[1/s]/kon[1/M*s] KD [nM] koff[1/s]/kon[1/M*s] KD [nM]
BMP-2 (BBBBBB) 7.54610
24/3.60610
5 2.09 4.05610
22/1.10610
6 36.8
Activin-bA (AAAAAA) No Binding N.A. 7.16610
24/3.52610
6 0.203
AB208 (BAAAAA) No Binding N.A. 8.24610
24/2.39610
6 0.344
AB204 (BABBAA) 1.85610
22/1.13610
6 16.4 1.87610
24/4.91610
5 0.381
AB211 (BBBBAA) 1.93610
22/4.07610
5 47.4 3.39610
24/6.46610
5 0.525
AB215 (BABBBA) No Binding N.A. 3.71610
24/1.61610
6 0.230
AB212 (BBBBBA) 8.48610
22/1.61610
5 526 1.60610
23/3.39610
6 0.472
The receptors were immobilized to the chip surface with the ligands flowed over the surface. The data were fit to a kinetic model (1:1 Langmuir binding with mass
transfer) in which KD is calculated as koff/kon. The table reports data from a single trial. No Binding indicates that the interaction was not detectable.
doi:10.1371/journal.pone.0026402.t001
Figure 3. Cripto Binding Experiments. (A) Activin-bA and (B) AB208
activities were tested in the presence and absence of Cripto. The results
are shown as Fold Induction of Smad2 luciferase reporter in HEK293
cells. The experiments were performed in triplicate and the error bars
are included.
doi:10.1371/journal.pone.0026402.g003
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phase chromatography step, the 1b_BMP dimer was purified close
to 100% homogeneity (Figure 4D). To test for activity, the purified
1b_BMP-9 was subjected to the same Smad1 luciferase reporter
assay. BMP-9 is known to signal through activation of the Smad1
pathway [37]. 1b_BMP-9 shows strong activation of the Smad1
reporter in a dose-dependent manner, indicating that the refolded
1b_BMP-9 is indeed properly folded and functional (Figure 5).
AB204, AB211, AB212, and AB215 display enhanced BMP-
2 properties
Using the classic BMP responsive mouse myoblast C2C12 cell
assay with a reporter sensitive to Smad1 activation, we have
identified four AB chimera ligands that exhibit the Smad1-
mediated signaling properties. The AB2 chimeras AB204, AB211,
AB212, and AB215 showed up-regulated signaling activity in the
C2C12 cell assays higher than that of BMP-2 (Figure 6A–D).
Overall, the chimeras displayed a 3- to 10-fold increase in
signaling response compared to BMP-2 with the maximal response
at 300 ng/ml for all the ligands.
We then checked to see if this increased signaling activity could
be attenuated by Noggin like BMP-2. Noggin is an extracellular
antagonist for BMP ligands including BMP2, and abolishes BMP-
mediated signaling by blocking both receptor-binding sites of the
ligand [38]. Unlike BMP-2, Activin-bA signaling is not blocked by
Noggin and is instead inhibited by the extracellular antagonist
Follistatin [39]. As predicted from the designed structural features
of these AB chimeras, they contain segments of the Activin-bA
protein sequence and they indeed exhibit different Noggin binding
properties as compared to BMP-2. Using the same Smad1-
mediated luciferase assay system, BMP-2 activity was significantly
blocked to near background levels in the presence of Noggin,
whereas the signaling activities of AB204, AB211, and AB215
remained unchanged in the absence or presence of Noggin
(Figure 7). Interestingly, the activity of the AB212 chimera is
partially blocked to ,75% of signaling levels by Noggin (Figure 7).
Receptor Binding Affinities and Specificities of AB204,
AB211, AB212, and AB215
The increased signaling activity recorded in the luciferase assays
may be a result of the AB2 chimeras possessing unique receptor
binding properties compared to BMP-2. AB204, AB211, AB212,
and AB215, all share one identical segment, segment 6a derived
from Activin-bA (Table S1). Segment 6 comprises beta strand 4
Figure 4. 1b_BMP-9 Purification. The refolding properties of BMP-9 and 1b_BMP-9 were compared using standard refolding conditions. The
Heparin sulfate chromatography elution profiles are shown for (A) BMP-9 and (B) 1b_BMP-9. (C) The eluted peaks for 1b_BMP-9 were visualized under
non-reducing conditions on SDS-PAGE gel. (D) The final product from 1b_BMP-9 refolding and purification is shown by SDS-PAGE gel, using non-
reducing conditions.
doi:10.1371/journal.pone.0026402.g004
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experiment was performed in triplicate and reported as Fold Induction with included error bars.
doi:10.1371/journal.pone.0026402.g005
Figure 6. Smad1 Activity Assays. BMP-2 activity was compared to AB2 library chimeras using a Smad1 dependent luciferase reporter in C2C12
cells. Results are shown as Fold Induction for (A) AB204, (B) AB211, (C) AB212, and (D) AB215. The experiments were performed in triplicate and the
error bars are included.
doi:10.1371/journal.pone.0026402.g006
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This region is known to contain residues important for type II
receptor binding for both BMP-2 [23] and Activin-bA [40]. Based
on this structural commonality, these AB2 chimeras might have
altered affinity for type II receptors compared to that of BMP-2.
To test this hypothesis, the binding affinity of the AB2 chimeras to
the type II receptor ActRII was measured using Biacore. With
ActRII-ECD immobilized to the chip surface, BMP-2 showed
medium affinity to ActRII-ECD with a binding affinity of
KD=36.8 nM (Table 1). Activin-bA showed a high binding
affinity of KD=0.203 nM, or ,180-fold higher than BMP-2
(Table 1). These calculated binding affinities for BMP-2 and
Activin-bA are in agreement with our previously data [22,30].
When the AB2 chimeras were measured against ActRII-ECD,
their ActRII-binding affinities were invariably near that of Activin-
bA (Table 1). Among them, AB215 possessed the highest affinity of
KD=0.230 nM, with AB204 (KD=0.381 nM) and AB212
(KD=0.472 nM) having slightly weaker affinity. AB211 had the
weakest affinity with KD=0.525 nM, which is ,2.6-fold weaker
than Activin-bA (Table 1). These results indicate that these AB2
chimeras possess high affinity for ActRII receptor like Activin-bA.
Since binding to a type I receptor is required for proper
signaling, the affinity of these AB2 chimeras for the type I receptor
BMPRIa (Alk-3) was also measured. BMPRIa is the preferred type
I receptor of BMP-2. When BMPRIa-ECD was immobilized,
BMP-2 displayed high affinity with KD=2.09 nM (Table 1). As
expected, no binding was detected when Activin-bA was flown
over the same surface (Table 1). Similar to the type II receptor
affinity data, these results are consistent with our previous binding
experiments [22,30]. Surprisingly, however, these four AB2
chimeras exhibited varying degrees of BMPRIa receptor-binding
affinity compared to BMP-2. AB204 has the highest affinity of the
chimeras with an affinity of KD=16.4 nM, or an 8-fold reduced
affinity compared to BMP-2 (Table 1). AB211 shows an even
weaker affinity than AB204, with KD=47.4 nM (,24-fold lower
than BMP-2) (Table 1). Both AB212 and AB215 show significant
loss in binding affinity to BMPRIa-ECD. AB212 affinity was
calculated to be KD=526 nM, or a ,250-fold decrease in affinity,
while binding affinity of AB215 to BMPRIa-ECD could not be
measured (Table 1). These results implicate that the enhanced
SMAD-mediated signaling ability of these designer AB2 chimera
does not result simply from the enhanced binding affinity of
receptor pairs utilized in nature by BMP-2, but likely from a mix
of signaling pathways through different pairs of receptors.
Discussion
Activin-bA plays important roles in numerous biological
functions including follicle and testicular development as well as
being implicated in regulation of glucose levels. More recently,
Activin-bA has been shown to be instrumental in maintaining
pluripotency or ‘stemness’ of cultured human embryonic stem cells
(hESCs) [3]. Typically, Activin-bA has been produced in the
laboratory either from transiently transfected cell lines [27] or
Figure 7. Noggin and Follistatin Inhibition Assays. The ability of Noggin and Follistatin to block ligand-induced signaling was measured using
a Smad1 luciferase reporter in C2C12 cells. The ligands are BMP-2, AB204, AB211, AB212, and AB215 from left to right. The activities are shown on
relative scale to the control sample (no antagonist treated) at 100% (see Methods). Four columns in each panel are activities tested at 30 ng/ml ligand
with and without the presences of 30, 100, and 300 ng/ml (a) Noggin or (b) Follistatin. The experiments were performed in triplicate and reported as
Fold Induction with included error bars.
doi:10.1371/journal.pone.0026402.g007
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its limited use because of a large production cost for a scale-up.
Despite a reported method of refolding Activin-bA in vitro [25], the
method appears difficult to reproduce satisfactorily. Using a
segment-swapping RASCH strategy with BMP-2 and Activin-bA,
we have demonstrated that a chimeric ligand, AB208 achieved our
initial goal to create a new designer molecule that is functionally
equivalent to Activin-bA but can be produced relatively easily by
chemical refolding. AB208’s refolding efficiency is comparable to
that of BMP-2 (Table S1) and, in cell signaling assays, it specifically
stimulated the Smad2 pathway in the same manner as Activin-bA
(Figure 2A; Figure S1). Additionally, AB208 was also shown to
bind the type II receptor ActRII (Table 1) and interact with the co-
receptor Cripto (Figure 3) equivalently to Activin-bA. In more
physiological experiments using cultured rat anterior pituitary
cells, addition of either AB208 or Activin-bA induced the release
of Follicle Stimulating Hormone (FSH) in a dose-dependent
manner (Figure S2). Further, AB208 has been confirmed to
maintain the pluripotency of hESCs in defined media just like
Activin-bA (unpublished data). Combined together, we conclude
that the RASCH strategy indeed led us to create a new designer
chimera AB208 that can be used effectively as a replacement for
Activin-bA.
It is general that some protein sequences are more readily
produced than others by chemical refolding. The exact under-
standing of why some TGFb superfamily members refold more
efficiently than others remains elusive. For instance, BMP-3 and
BMP-6 can be refolded to achieve crystallization-quality samples
relatively readily, but BMP-9, BMP-7 or Activin- bA are notably
difficult to refold readily [22]. Our study indicates that Segment 1
of BMP-2 (‘1b’) promotes efficient refolding of Activin-bA
significantly. When this ‘1b’ segment of BMP-2 was introduced
into BMP-9, the refolding efficiency of the new chimera, 1b_BMP-
9, was dramatically improved and achieved an overall yield of
,7%. When tested for functional activity, the refolded 1b_BMP-9
stimulated the Smad1 pathway (Figure 5). Because the yield of
recombinant BMP-9 is much lower, we could not obtain sufficient
amount of BMP-9 to compare the activity to 1b-BMP-9. So we
have not been able to obtain reliable data to compare 1b_BMP-9
to the recombinant BMP-9. There can be other factors noteworthy
to the recombinant 1b_BMP-9 and BMP-9. 1b_BMP-9 does not
have glycosylation modification. Such difference may result in the
difference of the activity in the Smad1-reporter assay when
compared to natural mammalian BMP-9. Nonetheless, it is clear
that 1b_BMP-9 shows dose-dependent reporter activation, and the
1b modification introduced into 1b_BMP-9 enabled us to
overcome the refolding barrier that we encountered with
recombinant BMP-9. The properties that allow the ‘1b’ segment
to facilitate and improve the refolding characteristics of TGFb
ligands need to be further refined to be universally applicable. For
instance, we have not been able to refold 1b_BMP-7. The ‘1b’
segment of BMP-2 contains 7 basic residues preceding the first
structurally conserved cysteine, Cys 14 of BMP-2 (Figure 1A). In
comparison, the N-terminus of Activin-bA and BMP-9 have only 1
or no basic residues, respectively. Both Arginine and Lysine have
been used as additives to induce proper protein refolding through
the suppression of protein aggregation [41,42]. Therefore, the
high concentration of these residues in the N-terminus of BMP-2
might function to reduce protein aggregation, thereby promoting
refolding. How incorporation of the ‘1b’ segment of BMP-2
further improves refolding of TGF-beta superfamily ligands
remains to be better understood.
In addition to refolding specific targets such as Activin-bA and
BMP-9, RASCH strategy yielded several AB chimeras with novel
signaling properties. Four AB2 library chimeras (AB204, AB211,
AB212, and AB215), showed a significant increase in activity
compared to BMP-2 in cell signaling assays (Figure 6). The basis
for this increased activity appears to be a direct result of their
significantly increased binding affinity for the type II receptor
ActRII. All four chimeras possess binding affinity for ActRII
comparable to Activin-bA, which is ,180-fold higher than BMP-
2’s binding affinity (Table 1). Surprisingly, these AB2 chimeras
also show varying degrees of reduction in type I receptor-binding
affinity to BMPRIa compared to BMP-2 (Table 1). A common
sequence region of these four AB2 chimeras is that they all contain
segment 6 of Activin-bA (Table S1). Previous structural studies
showed that this region is a major site for type II receptor binding
[29,40]. The type II receptor binding site is confined within one
subunit of the dimeric ligand, and thus inclusion of segment 6 from
Activin-bA would transfer the majority of interface residues into
the chimeras. Unlike type II receptor binding, type I receptor
binding is composed of residues residing in the pre-helix loop and
a-helix of one ligand monomer and residues residing in the inside
of the fingers from the other ligand monomer [43]. Therefore,
residues in the Activin-bA segments of the chimeras unfavorable
towards BMPRIa binding would contribute to both type I receptor
binding sites. Unlike type II binding interface, however, defining
the segmental origin of residues responsible for specifying type I
receptor binding interface is not clear. The structural basis for this
reduced affinity is not readily apparent and requires further
characterization.
Among the four AB2 chimera, AB215 is peculiar in that it
displays high signaling activity despite having no detectable
binding to BMPRIa (Figure 6; Table 1). The apparent disconnect
between receptor-binding specificity and signaling capability could
have two possible explanations. First, the preference for the type I
receptor has shifted away from BMPRIa to a different type I
receptor including BMPRIb. We have previously shown that a
single residue in BMP-3 is responsible for a 30-fold specificity
difference for ActRIIb over ActRII [22]. Further, GDF-5’s type I
receptor preference has also been isolated to a single residue [21].
Therefore, the chimera AB215 may have changed its receptor
preference. The C2C12 cells used in our assays are known to
express BMPRIa (Alk3) along with BMPRIb (Alk6) and ActRIa
(Alk2) and the chimeras could activate the Smad1 reporter using
any of these receptors, but we have not been able to evaluate
AB215’s affinity towards BMPRIb or ActRIa because their ECD
reagents are not available for experimental tests. The second
possible explanation is that type II receptor binding is the pivotal
component for formation of active signaling complexes on the cell
surface. The low dissociation rates associated with the tight type II
receptor binding would allow the chimeras to bind to the cell
surface for long periods of time, effectively increasing their local
concentrations to promote binding to type I receptors. Addition-
ally, the receptors are constrained to the membrane surface by
their transmembrane domain. So the combination of increased
retention time bound to the cell surface with the reduced freedom
of the receptors may be sufficient to overcome the decreased type I
receptor binding affinity. Even if type I and type II receptors
directly interact with each other on the cell surface independent of
ligand [44], the reduced affinity of the chimeras for the type I
receptor might be overcome by the very high affinity of the type II
receptors which bring the type I receptors into the signaling
complex.
In addition to having increased signaling activity, AB204,
AB211, AB212, and AB215 also possess insensitivity to Noggin. At
a Noggin level that completely blocks BMP2 signaling, AB204 and
AB215, showed no sensitivity to Noggin, whereas AB211 and
RASCH Design of TGFb Superfamily Ligands
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specific antagonist Follistatin, only AB204 showed dose-dependent
inhibition of Smad1-mediated signals by Follistatin, whereas other
ligands are not significantly affected by Follistatin (Figure 7B).
Since AB215 is the only one among four AB2 chimera, which is
completely resistant to both Noggin and Follistatin, AB215
appears to be the sequence furthest from either Activin or
BMP2 in terms of sequence similarity to Activin or BMP2, while
AB204 is closer to Activin and AB211 and AB212 are to BMP2.
The complete insensitivity to Noggin binding appears to require
segment 6 of with either segment 2 or segment 5 be replaced (in
these cases by those of of Activin-bA). Incorporation of only
segment 6 may be partly responsible for Noggin insensitivity
displayed by AB212 (Figure 5). Recently, it was reported that the
mutation of a single residue in BMP-7 results in a loss in sensitivity
to Noggin binding [45]. In GDF-5, a different point mutation has
been identified which contributes to Noggin insensitivity [46]. The
equivalent residues in our RASCH’s segmental design are located
in segment 2 and segment 3, respectively, but they differ from each
other. Data obtained from these AB2 chimeras are consistent with
the notion that the residues responsible for the increased binding
affinity to ActRII appear overlapping with those that confer
Noggin sensitivity [38].
The conserved architecture found in the mature domain of the
TGF-b superfamily ligands allows for the RASCH strategy to be
applied to other members of the TGF-b superfamily. Since the
same secondary structural features exist in all ligands, their natural
functional boundary regions can be swapped to transfer a larger
number of receptor binding residues at one time, allowing for the
ability to mix different receptor binding properties of a new
chimera library. For instance, segment 6 contains the majority of
the residues shown to affect type II receptor binding in numerous
ligands. One could envision making a designer molecule that binds
TGFbRII but uses BMPRIa as the type I receptor, or one could
create a Cripto-independent Nodal molecule by mixing segments
from a ligand that does not bind Cripto. These unnatural receptor
arrangements may stimulate signaling pathways otherwise not
naturally activated by any natural ligands in specific tissue type
cells. Thus, the ability to engineer novel receptor binding patterns
of RASCH-modified (‘‘RASCHonized’’) chimeric ligands of TGF-
b superfamily may provide a novel platform never existent in
nature but conceivably to target them to a specific receptor pair for
therapeutic purposes.
Methods
Generation of TGFb Chimeras
To create the AB2 chimera library, the mature domains of
human BMP-2 and human Activin-bA were divided into 6
segments (segments 1 through 6) each and primers were designed
for each segment. An overlapping PCR strategy was used to mix
the various segments together to generate full-length PCR
fragment of each chimera. To generate the 1b_BMP-9 chimera,
segment 1 of BMP-2 replaced the corresponding N-terminus of
BMP-9. Outer primers for all full-length PCR fragments were
constructed to incorporate a 59 NdeI site and a 39 XhoI site for
cloning into pET21a expression vector. The desired protein
sequences were confirmed by DNA sequencing.
Protein Expression and Purification
All AB2 library chimeras, 1b_BMP-9, and BMP-2 were
expressed in E. coli as inclusion bodies. The inclusion bodies were
isolated, purified, and refolded using a modified protocol [47]. The
refolded ligands were purified using Hi-trap Heparin sulfate (GE
Healthcare) and reverse phase (GraceVydac) chromatography.
Activin-bA was expressed and purified from a stably transfected
CHO cell line [48]. Noggin was expressed in E. coli as inclusion
bodies and purified as previously described [38]. The ECD of
human BMPRIa (residues 1–129) was expressed in E. coli as a
thioredoxin fusion protein using a modification of published
procedures [23,43]. The ECD of mouse ActRII (residues 1–102)
was expressed and purified from Pichia pastoris as previously
described [49].
Smad1 Luciferase Assays in C2C12 Cells
Smad1-dependent luciferase assays were performed as previ-
ously described [50]. In brief, C2C12 myoblast cells [51] are
cultured in Dulbecco’s minimum essential medium (DMEM)+5%
FBS supplemented with L-Glutamine and antibiotics. For
luciferase reporter assays, cells were trypsinized, washed twice
with PBS and plated into 48-well plates with DMEM+1% FBS.
The cells were transfected with 21147Id1-luciferase construct
containing the Smad binding sites (Id1-Luc) [50,52], a Smad1
expression construct, and a reference reporter, pRL-TK plasmid
by using Fugene6 (Roche) according to the manufacturer’s
instruction. Increasing amounts of BMP-2 or the various AB2
chimeras added 24 hours after transfection. Luciferase activity was
measured 24 hours after stimulation. The activity of the luciferase
reporter was normalized for transfection efficiency by using
Renilla luciferase activity, and is reported in fold-induction
relative to control values. To test for the ability of Noggin and
Follistatin to attenuate the Smad1 signaling of the ligands, the
luciferase assays were repeated as described above, with a set dose
of Noggin and Follistatin included in the assay. 1b_BMP-9 activity
was tested in the same manner as described for the AB2 chimeras.
Smad2 Luciferase Assays in HEK293 Cells
HEK293T cells [53] were seeded into 24-well plates coated with
polylysine at a density of 150,000 cells/well. After 24 h cells were
transfected overnight with a mixture of A3 Lux (25 ng) and b-
galactosidase (25 ng) reporter plasmids, the transcription factor
FAST2 (50 ng), and empty pCDNA3 vector (400 ng) using
PerfectinH transfection reagent (GenLantis) according to the
manufacturer’s recommendations. Then the cells were treated
with increasing doses of activin- bA or AB2 chimeras for 16–24 h.
The cells were harvested in ice-cold lysis buffer (1% Triton X-100
in 25 mM glycylglycine, 4 nM EGTA, 15 mM MgSO4 containing
1 mM dithiothreitol) and assayed for luciferase and b-galactosi-
dase activities using standard methods. To assess the ability of the
AB2 chimeras to bind known TGF-b co-receptors, the HEK293T
cells were treated with increasing doses of Activin-bA or AB2
chimeras for 16–24 h in the presence or absence of transfected
Cripto (mouse Cripto construct was a generous gift from Malcolm
Whitman (Department of Cell Biology, Harvard Medical School,
Boston, MA). Activity was then measured as previously described
[23].
Surface Plasmon Resonance (BIAcore) Affinity Studies
The affinity of the ligands to the ECDs of BMPRIa and ActRII
was measured using a Biacore 2000 (GE Healthcare) and the data
were analyzed with BIAevaluation software ver. 4.1 (GE
Healthcare). Using primary amine coupling, the receptor ECDs
were immobilized on a CM5 chip independently using flow cells 2
and 3, while flow cell 1 was left blank, no immobilized protein, as a
negative control. For kinetic analysis, all tests were performed in
duplicate using a minimum of five concentrations, plus a zero
concentration. The data were fit using a global 1:1 Langmuir
binding with mass transfer model.
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Figure S1 Phospho-Smad2 assays. An increase in phos-
phor-SMAD1 or phospho-SMAD2 levels were measured in cells
treated with different ligands (BMP-2, AB208, AB209, AB210).
Unlike BMP-2, these ligands resulted in phosphorylating SMAD2.
(DOC)
Figure S2 RAPs assay. Using cultured rat anterior pituitary
cells, addition of either AB208, AB209, AB210 or Activin-bA
induced the release of Follicle Stimulating Hormone (FSH) in a
dose-dependent manner at varying degrees.
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Table S1 Segment contents of AB2 library chimera and
their refolding efficiency.
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